


Oritavancin diphosphate

Cat. No.:	HY-B1831A		
CAS No.:	192564-14-0		
Molecular Formula:	C ₈₆ H ₁₀₃ Cl ₃ N ₁₀ O ₃₄ P ₂		
Molecular Weight:	1989.09		
Target:	Bacterial; Antibiotic		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 41.67 mg/mL (20.95 mM; Need ultrasonic)

Concentration	Solvent	Mass	Preparing Stock Solutions		
			1 mg	5 mg	10 mg
1 mM			0.5027 mL	2.5137 mL	5.0274 mL
5 mM			0.1005 mL	0.5027 mL	1.0055 mL
10 mM			0.0503 mL	0.2514 mL	0.5027 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Oritavancin diphosphate (LY333328 diphosphate) is a semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Target: Antibacterial. Oritavancin is a lipoglycopeptide. Oritavancin has completed clinical trials and submitted a new drug application for treatment of skin infections.

CUSTOMER VALIDATION

-
- Emerg Microbes Infect. 2019;8(1):503-515.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Arhin FF, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008 May;52(5):1597-1603.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA